Cagrilintide + Semaglutide Blend

Key points

• The blend combines cagrilintide, an amylin analogue, with semaglutide, a GLP-1 medicine.
• It is studied for weight loss as a combination called CagriSema.
• It is in late stage trials and not approved anywhere.
• In the UK it would be available only within a clinical trial.

Quick facts

What it is

Cagrilintide and semaglutide combination (CagriSema)

Studied for

Weight loss and obesity

Stage

Late stage trials; not approved

UK status

Investigational; available only in clinical trials

How it works

The two parts act on complementary fullness pathways: semaglutide copies the gut hormone GLP-1, while cagrilintide mimics amylin. Using both at once is meant to reduce appetite more than either alone. See the cagrilintide and semaglutide entries for detail.

What the evidence shows

Trials of the combination have reported large average weight loss over about a year. The full late stage results and the regulatory decisions are still to come, and the combination is not yet approved.

What it does not settle

• The full phase 3 picture and approvals are still to come.
• Long term safety of the combination is not established.
• Products sold online as this blend are unlicensed and unverified.

Side effects

Common

• As with other medicines acting on gut hormones, stomach effects such as nausea are expected, especially while the dose is raised.

Less common but serious

• Because the combination is investigational, its full safety profile is still being established.
• Products sold online are unlicensed, and their dose and contents cannot be verified.

Report any suspected side effect through the MHRA Yellow Card scheme.

UK legal status and access

This combination has no marketing authorisation, so it is not prescribed by registered clinics or pharmacies. In the UK the only route is a clinical trial. Products sold online are unlicensed.

Common questions